Mannkind Revenue Growth Rates (MNKD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Mannkind Corporation  (NASDAQ: MNKD)
 

MNKD's Revenue Growth by Quarter and Year

Mannkind's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MNKD/growth
https://api.csimarket.com/api/v1/companies/MNKD/fundamentals
https://api.csimarket.com/api/v1/companies/MNKD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MNKD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 101.87
2nd Quarter June 109.37
1st Quarter March 90.17
FY 301.41

MNKDs Annual Revenue
Mannkind's Revenue in the fiscal year 2025 $ 348.97 millions
Mannkind's Revenue in the fiscal year 2024 $ 285.50 millions
Mannkind's Revenue in the fiscal year 2023 $ 198.96 millions
Mannkind's Revenue in the fiscal year 2022 $ 99.77 millions
Mannkind's Revenue in the fiscal year 2021 $ 75.44 millions




MNKD Revenue third quarter 2026 Y/Y Growth Comment
Mannkind Corporation reported Revenue improvement of 24.04% year on year in the third quarter 2026, to $ 101.87 millions, this is lower than Mannkind Corporation's recent average Revenue rise of 59.12%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 118 other companies have achieved higher Revenue growth. While Mannkind Corporation' s Revenue rise of 24.04% ranks overall at the positon no. 2484 in the third quarter 2026.


MNKD Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 24.04 %
2nd Quarter June 42.91 %
1st Quarter March 15.09 %
FY   -

Financial Statements
Mannkind's third quarter 2026 Revenue $ 101.87 millions MNKD's Income Statement
Mannkind's third quarter 2025 Revenue $ 82.13 millions Quarterly MNKD's Income Statement


MNKD Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -6.86 %
2nd Quarter June 21.29 %
1st Quarter March -19.46 %
FY (Year on Year)   -


Back to MNKD Growth rate Comparisons >> Back to MNKD Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #119
Healthcare Sector #358
Overall #2484

Revenue Y/Y Growth Statistics
High Average Low
285.62 % 59.12 % -92.26 %
(Sep 30 2019)   (Jun 30 2018)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #119
Healthcare Sector #358
Overall #2484
Revenue Y/Y Growth Statistics
High Average Low
285.62 % 59.12 % -92.26 %
(Sep 30 2019)   (Jun 30 2018)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Mannkind's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
258.72 % 3.41 % -100 %
(Dec 31 2018)  


MNKD's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Mannkind Corporation disclosed decline in Revenue from the second quarter by -6.86% to $ 101.87 millions, from $ 109.37 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Revenue quarter on quarter growth. While Mannkind's Revenue growth quarter on quarter, overall rank is 497.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #98
Overall #497
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #98
Overall #497
Revenue Q/Q Growth Statistics
High Average Low
258.72 % 3.41 % -100 %
(Dec 31 2018)  


MNKD's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Mannkind Corporation disclosed decline in Revenue from the second quarter by -6.86% to $ 101.87 millions, from $ 109.37 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Revenue quarter on quarter growth. While Mannkind's Revenue growth quarter on quarter, overall rank is 497.


Mannkind's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 413.37
Y / Y Revenue Growth (TTM) 31.74 %
Year on Year Revenue Growth Overall Ranking # 791
Seqeuential Revenue Change (TTM) 5.01 %
Seq. Revenue Growth (TTM) Overall Ranking # 2494


Cumulative Revenue growth Comment
Although Mannkind's Annual Revenue growth year on year were below company's average 59.12% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 31.74% year on year, from 30.46% in Jun 30 2026.

In the Healthcare sector 164 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 274 to 791.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 119
Healthcare Sector # 165
Overall # 791

Revenue TTM Y/Y Growth Statistics
High Average Low
285.62 %
 59.12 %
-92.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 119
Sector # 358
S&P 500 # 2494
Cumulative Revenue growth Comment
Although Mannkind's Annual Revenue growth year on year were below company's average 59.12% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 31.74% year on year, from 30.46% in Jun 30 2026.

In the Healthcare sector 164 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 274 to 791.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 119
Healthcare Sector # 165
Overall # 791

Revenue TTM Y/Y Growth Statistics
High Average Low
285.62 %
59.12 %
-92.26 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 119
Sector # 358
S&P 500 # 2494




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MNKD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions


About Mannkind Revenue Growth Rates (MNKD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mannkind Corp (CIK 899460).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-449776
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mannkind Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.